Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood⁻Brain Barrier

doi:10.3390/biomimetics3010004

Review

. 2018 Mar 7;3(1):4.

doi: 10.3390/biomimetics3010004.

Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood⁻Brain Barrier

Joseph S D'Arrigo¹

Affiliations

PMID: 31105226
PMCID: PMC6352688
DOI: 10.3390/biomimetics3010004

Review

Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood⁻Brain Barrier

Joseph S D'Arrigo. Biomimetics (Basel). 2018.

. 2018 Mar 7;3(1):4.

doi: 10.3390/biomimetics3010004.

Author

Joseph S D'Arrigo¹

Affiliation

¹ Cavitation-Control Technology Inc., Farmington, CT 06032, USA. cavcon@ntplx.net.

PMID: 31105226
PMCID: PMC6352688
DOI: 10.3390/biomimetics3010004

Abstract

Over the past decades, a frequent co-morbidity of cerebrovascular pathology and Alzheimer's disease has been observed. Numerous published studies indicate that the preservation of a healthy cerebrovascular endothelium can be an important therapeutic target. By incorporating the appropriate drug(s) into biomimetic (lipid cubic phase) nanocarriers, one obtains a multitasking combination therapeutic, which targets certain cell surface scavenger receptors, mainly class B type I (i.e., SR-BI), and crosses the blood⁻brain barrier. This targeting allows for various cell types related to Alzheimer's to be simultaneously searched out for localized drug treatment in vivo.

Keywords: Alzheimer’s disease; SR-BI; biomimetic nanocarriers; blood–brain barrier; dementia; drug targeting; lipid cubic phase; nanoemulsion; scavenger receptors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. J.S.D. is employed at Cav-Con Inc.

Cited by

Effect of Bacterial Amyloid Protein Phenol-Soluble Modulin Alpha 3 on the Aggregation of Amyloid Beta Protein Associated with Alzheimer's Disease.
Peng B, Xu S, Liang Y, Dong X, Sun Y. Peng B, et al. Biomimetics (Basel). 2023 Oct 1;8(6):459. doi: 10.3390/biomimetics8060459. Biomimetics (Basel). 2023. PMID: 37887589 Free PMC article.
Nanotargeting of Drug(s) for Delaying Dementia: Relevance of Covid-19 Impact on Dementia.
D'Arrigo JS. D'Arrigo JS. Am J Alzheimers Dis Other Demen. 2020 Jan-Dec;35:1533317520976761. doi: 10.1177/1533317520976761. Am J Alzheimers Dis Other Demen. 2020. PMID: 33307726 Free PMC article. Review.
Biomimetic Nanocarrier Targeting Drug(s) to Upstream-Receptor Mechanisms in Dementia: Focusing on Linking Pathogenic Cascades.
D'Arrigo JS. D'Arrigo JS. Biomimetics (Basel). 2020 Mar 20;5(1):11. doi: 10.3390/biomimetics5010011. Biomimetics (Basel). 2020. PMID: 32244941 Free PMC article. Review.

References

1. D’Arrigo J.S. Alzheimer’s disease, brain injury, and CNS nanotherapy in humans: Sonoporation augmenting drug targeting. Med. Sci. 2017;5:29.
1. D’Arrigo J.S. Nanotherapy for Alzheimer’s disease and vascular dementia: Targeting senile endothelium. Adv. Colloid Interface Sci. 2018;251:44–54. doi: 10.1016/j.cis.2017.12.002. - DOI - PubMed
1. Cooper L.L., Mitchell G.F. Aortic stiffness, cerebrovascular dysfunction, and memory. Pulse. 2016;4:69–77. doi: 10.1159/000448176. - DOI - PMC - PubMed
1. Dichgans M., Leys D. Vascular cognitive impairment. Circ. Res. 2017;120:573–591. doi: 10.1161/CIRCRESAHA.116.308426. - DOI - PubMed
1. Greenberg S.M. Vascular disease and neurodegeneration: Advancing together. Lancet Neurol. 2017;16:333. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] D’Arrigo J.S. Alzheimer’s disease, brain injury, and CNS nanotherapy in humans: Sonoporation augmenting drug targeting. Med. Sci. 2017;5:29.

[2] D’Arrigo J.S. Alzheimer’s disease, brain injury, and CNS nanotherapy in humans: Sonoporation augmenting drug targeting. Med. Sci. 2017;5:29.

[3] D’Arrigo J.S. Nanotherapy for Alzheimer’s disease and vascular dementia: Targeting senile endothelium. Adv. Colloid Interface Sci. 2018;251:44–54. doi: 10.1016/j.cis.2017.12.002. - DOI - PubMed

[4] D’Arrigo J.S. Nanotherapy for Alzheimer’s disease and vascular dementia: Targeting senile endothelium. Adv. Colloid Interface Sci. 2018;251:44–54. doi: 10.1016/j.cis.2017.12.002. - DOI - PubMed

[5] Cooper L.L., Mitchell G.F. Aortic stiffness, cerebrovascular dysfunction, and memory. Pulse. 2016;4:69–77. doi: 10.1159/000448176. - DOI - PMC - PubMed

[6] Cooper L.L., Mitchell G.F. Aortic stiffness, cerebrovascular dysfunction, and memory. Pulse. 2016;4:69–77. doi: 10.1159/000448176. - DOI - PMC - PubMed

[7] Dichgans M., Leys D. Vascular cognitive impairment. Circ. Res. 2017;120:573–591. doi: 10.1161/CIRCRESAHA.116.308426. - DOI - PubMed

[8] Dichgans M., Leys D. Vascular cognitive impairment. Circ. Res. 2017;120:573–591. doi: 10.1161/CIRCRESAHA.116.308426. - DOI - PubMed

[9] Greenberg S.M. Vascular disease and neurodegeneration: Advancing together. Lancet Neurol. 2017;16:333. - PubMed

[10] Greenberg S.M. Vascular disease and neurodegeneration: Advancing together. Lancet Neurol. 2017;16:333. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood⁻Brain Barrier

Affiliation

Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood⁻Brain Barrier

Author

Affiliation

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous